Restricted accessResearch articleFirst published online 2025-03
Association of PNPLA3 rs738409 C > G and rs2896019 T > G Polymorphisms with Nonalcoholic Fatty Liver Disease in a Turkish Population from Adıyaman Province
The purpose of this study was to investigate the effect of patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 C > G and rs2896019 T > G polymorphisms on genetic susceptibility to nonalcoholic fatty liver disease (NAFLD) in a Turkish population from Adıyaman province, located in the Southeast Anatolia Region of Turkey.
Materials and Methods:
This hospital-based molecular epidemiological case-control study analyzed the PNPLA3 rs738409 C > G and rs2896019 T > G polymorphisms in 335 NAFLD cases and 410 healthy controls. Genotype frequencies were determined using real-time polymerase chain reaction with the TaqMan assay. The association with NAFLD susceptibility was evaluated by calculating odds ratios (ORs) and 95% confidence intervals (CIs) using an unconditional logistic regression model.
Results:
We found that the PNPLA3 rs738409 C > G (CC vs. GG: OR = 1.90, 95% CI = 1.05-3.44) and rs2896019 T > G (TT vs. GG: OR = 3.24, 95% CI = 1.44-7.27) polymorphisms were linked to an increased risk of NAFLD in almost all genetic models (p < 0.05). In addition, the PNPLA3 Grs738409/Grs2896019 haplotype was associated with NAFLD development (p < 0.05). Significant differences in alanine aminotransferase and aspartate aminotransferase enzyme levels were observed across the genotypes of these polymorphisms (p < 0.05).
Conclusion:
This is the first study on PNPLA3 single nucleotide polymorphisms (SNPs) and NAFLD in the Turkish population of Adıyaman Province, Southeast Anatolia. Our findings suggest that the PNPLA3 rs738409 C > G and rs2896019 T > G polymorphisms, along with their haplotypes, may influence NAFLD susceptibility. Further independent studies with larger sample sizes and diverse populations are needed to confirm these results.
Get full access to this article
View all access options for this article.
References
1.
AkkizH, TaskinE, KaraogullarindanU, et al.The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease. Medicine (Baltimore), 2021; 100(19):e25893; doi: 10.1097/MD.0000000000025893).
2.
AnsteeQM, DarlayR, CockellS, et al.; EPoS Consortium Investigators. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆). J Hepatol, 2020; 73(3):505-515; doi: 10.1016/j.jhep.2020.04.003
3.
BasuRayS, WangY, SmagrisE, et al.Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci U S A, 2019; 116(19):9521-9526; doi: 10.1073/pnas.1901974116
4.
BaulandeS, LasnierF, LucasM, PairaultJ. Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage. J Biol Chem, 2001; 276(36):33336-33344; doi: 10.1074/jbc.M105193200
5.
BruntEM, JanneyCG, Di BisceglieAM, et al.Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999; 94(9):2467-2474; doi: 10.1111/j.1572-0241.1999.01377.x
6.
BruschiFV, TardelliM, ClaudelT, et al.PNPLA3 expression and its impact on the liver: Current perspectives. Hepat Med, 2017; 9:55-66; doi: 10.2147/HMER.S125718
7.
BuzzettiE, PinzaniM, TsochatzisEA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism, 2016; 65(8):1038-1048; doi: 10.1016/j.metabol.2015.12.012
8.
CarlssonB, LindénD, BrolénG, et al.Review article: The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2020; 51(12):1305-1320; doi: 10.1111/apt.15738
CherubiniA, CasiratiE, TomasiM, ValentiL. PNPLA3 as a therapeutic target for fatty liver disease: The evidence to date. Expert Opin Ther Targets, 2021; 25(12):1033-1043; doi: 10.1080/14728222.2021.2018418
11.
DaiG, LiuP, LiX, et al.Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis. Medicine (Baltimore), 2019; 98(7):e14324; doi: 10.1097/MD.0000000000014324
12.
DeğertekinB, TozunN, DemirF, et al.The changing prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Turkey in the last decade. Turk J Gastroenterol, 2021; 32(3):302-312; doi: 10.5152/tjg.2021.20062
13.
DelikA, AkkızH, DinçerS. The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease. Indian J Gastroenterol, 2020; 39(1):84-91; doi: 10.1007/s12664-020-01026-x
14.
DemirtasCO, ErenF, YilmazD, et al.Does genetic variation in PNPLA3, TM6SF2 and HSD17B13 have a role in the development or prognosis of hepatocellular carcinoma in Turkish patients with Hepatitis B? J Gastrointestin Liver Dis, 2024; 33(2):203-211; doi: 10.15403/jgld-5474
15.
DiehlAM, DayC. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med, 2017; 377(21):2063-2072; doi: 10.1056/NEJMra1503519
16.
DiStefanoJK, KingsleyC, Craig WoodG, et al.Genome-wide analysis of hepatic lipid content in extreme obesity. Acta Diabetol, 2015; 52(2):373-382; doi: 10.1007/s00592-014-0654-3
17.
DongXC. PNPLA3-A potential therapeutic target for personalized treatment of chronic liver disease. Front Med (Lausanne), 2019; 6:304; doi: 10.3389/fmed.2019.00304
18.
GaudermanW, MorrisonJ. QUANTO 1.1: A Computer Program for Power and Sample Size Calculations for Genetic-Epidemiology Studies. 2006. Available from: http://hydra.usc.edu/gxe
19.
GiudiceEM, GrandoneA, CirilloG, et al.The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One, 2011; 6(11):e27933; doi: 10.1371/journal.pone.0027933
20.
HuangY, CohenJC, HobbsHH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem, 2011; 286(43):37085-37093; doi: 10.1074/jbc.M111.290114
21.
HusseiniAA. Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin. Mol Biol Rep, 2024; 51(1):845; doi: 10.1007/s11033-024-09787-w
22.
IdilmanR, KaratayliSC, KabacamG, et al.The role of PNPLA3 (rs738409) c>g variant on histological progression of non-alcoholic fatty liver disease. Hepatol Forum, 2020; 1(3):82-87; doi: 10.14744/hf.2020.2020.0023
23.
IoannouGN. Epidemiology and risk-stratification of NAFLD-associated HCC. J Hepatol, 2021; 75(6):1476-1484; doi: 10.1016/j.jhep.2021.08.012
24.
IslekEE, SazciA, OzelMD, AygunC. Genetic variants in the PNPLA3 gene are associated with nonalcoholic steatohepatitis. Genet Test Mol Biomarkers, 2014; 18(7):489-496; doi: 10.1089/gtmb.2014.0019
25.
KienesbergerPC, ObererM, LassA, ZechnerR. Mammalian patatin domain containing proteins: A family with diverse lipolytic activities involved in multiple biological functions. J Lipid Res, 2009; 50 (Suppl):S63-S68; doi: 10.1194/jlr.R800082-JLR200
26.
KumariM, SchoiswohlG, ChitrajuC, et al.Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab, 2012; 15(5):691-702; doi: 10.1016/j.cmet.2012.04.008
27.
Larrieta-CarrascoE, FloresYN, Macías-KaufferLR, et al.Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp Mol Pathol, 2018; 104(1):50-58; doi: 10.1016/j.yexmp.2018.01.001
28.
LeeY, ChoEJ, ChoeEK, et al.Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population. Sci Rep, 2024; 14(1):9753; doi: 10.1038/s41598-024-60152-0
29.
LuukkonenPK, NickA, Hölttä-VuoriM, et al.Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids. JCI Insight, 2019; 4(16):e127902; doi: 10.1172/jci.insight.127902
30.
NamjouB, LingrenT, HuangY, et al.; eMERGE Network. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE network. BMC Med, 2019; 17(1):135; doi: 10.1186/s12916-019-1364-z
31.
NjeiB, Al-AjlouniYA, UgwendumD, et al.Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: A systematic review. Transl Gastroenterol Hepatol, 2024; 9:11; doi: 10.21037/tgh-23-31
32.
ParkSL, LiY, ShengX, et al.Genome-wide association study of liver fat: The multiethnic cohort adiposity phenotype study. Hepatol Commun, 2020; 4(8):1112-1123; doi: 10.1002/hep4.1533
33.
PingitoreP, PirazziC, MancinaRM, et al.Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta, 2014; 1841(4):574-580; doi: 10.1016/j.bbalip.2013.12.006
34.
RomeoS, KozlitinaJ, XingC, et al.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet, 2008; 40(12):1461-1465; doi: 10.1038/ng.257
35.
RossoC, CavigliaGP, BiroloG, et al.Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2023; 21(13):3314-3321; doi: 10.1016/j.cgh.2023.04.024
SalariN, DarvishiN, MansouriK, et al.Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: A systematic review and meta-analysis. BMC Endocr Disord, 2021; 21(1):125; doi: 10.1186/s12902-021-00789-4
38.
SoléX, GuinóE, VallsJ, et al.SNPStats: A web tool for the analysis of association studies. Bioinformatics, 2006; 22(15):1928-1929; doi: 10.1093/bioinformatics/btl268
39.
SongG, XiaoC, WangK, et al.Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population. Medicine (Baltimore), 2016; 95(33):e4569; doi: 10.1097/MD.0000000000004569
40.
SookoianS, PirolaCJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology, 2011; 53(6):1883-1894; doi: 10.1002/hep.24283
41.
StasinouE, ArgyrakiM, SotiriadouF, et al.Association between rs738409 and rs2896019 single-nucleotide polymorphisms of phospholipase domain-containing protein 3 and susceptibility to nonalcoholic fatty liver disease in Greek children and adolescents. Ann Gastroenterol, 2022; 35(3):297-306; doi: 10.20524/aog.2022.0706
42.
StenderS, KozlitinaJ, NordestgaardBG, et al.Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet, 2017; 49(6):842-847; doi: 10.1038/ng.3855
43.
TilsonSG, MorellCM, LenaertsAS, et al.Modeling PNPLA3-associated NAFLD using human-ınduced pluripotent stem cells. Hepatology, 2021; 74(6):2998-3017; doi: 10.1002/hep.32063
44.
UygunA, OzturkK, DemirciH, et al.The association of nonalcoholic fatty liver disease with genetic polymorphisms: A Multicenter Study. Eur J Gastroenterol Hepatol, 2017; 29(4):441-447; doi: 10.1097/MEG.0000000000000813
45.
ValentiLVC, CherubiniA. To be or not to be: The quest for patatin-like phospholipase domain containing 3 p.I148M Function. Hepatology, 2021; 74(6):2942-2944; doi: 10.1002/hep.32096
46.
WilsonPA, GardnerSD, LambieNM, et al.Characterization of the human patatin-like phospholipase family. J Lipid Res, 2006; 47(9):1940-1949; doi: 10.1194/jlr.M600185-JLR200
47.
YeQ, ZouB, YeoYH, et al.Global prevalence, incidence, and outcomes of non-obese or lean nonalcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2020; 5(8):739-752; doi: 10.1016/S2468-1253(20)30077-7
48.
YounossiZM. Non-alcoholic fatty liver disease-A global public health perspective. J Hepatol, 2019; 70(3):531-544; doi: 10.1016/j.jhep.2018.10.033
49.
YounossiZM, GolabiP, PaikJM, et al.The global epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A systematic review. Hepatology, 2023; 77(4):1335-1347; doi: 10.1097/HEP.0000000000000004
50.
ZengMD, FanJG, LuLG, et al.; Chinese National Consensus Workshop on Nonalcoholic Fatty Liver Disease. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J Dig Dis, 2008; 9(2):108-112; doi: 10.1111/j.1751-2980.2008.00331.x
51.
ZhangL, YouW, ZhangH, et al.PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: A meta-analysis. J Gastroenterol Hepatol, 2015; 30(5):821-829; doi: 10.1111/jgh.12889
52.
ZhaoY, ZhaoW, MaJ, et al.Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies. Medicine (Baltimore), 2023; 102(10):e33110; doi: 10.1097/MD.0000000000033110
